Mergers & AcquisitionsMedium•5 November 2026•
1 min read
ANI Pharmaceuticals Offers to Acquire Egetis Therapeutics to Expand Rare Disease Portfolio
Key Facts
1ANI Pharmaceuticals announced a recommended public offer to acquire Egetis Therapeutics AB to expand its rare disease business scope.
ANI Pharmaceuticals announced a recommended public offer to acquire Egetis Therapeutics AB to expand the scope and scale of its rare disease business segment. GlobeNewswire reported that the offer extends to Egetis' shares, convertible debt, and warrants, with the cash consideration set at SEK 11.25 per share.
ANIP closed at $71.65 on November 4, 2026, having traded between a low of $71.36 and a high of $74.00 during that session. The acquisition proposal follows an announcement by Egetis on November 4, 2026, regarding a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for $190 million in gross proceeds.